AAV Vector Manufacturing: From Process Development to GMP Readiness

AAV, or adeno-associated virus, is a small virus widely used in gene therapy to deliver therapeutic genetic material into target cells. In gene therapy development, AAV vectors are engineered to carry a therapeutic gene or other genetic sequence that may help address the underlying cause of disease. AAV is widely used because of its clinical track record, tissue targeting potential, and suitability for a range of in vivo gene therapy applications.

AAV vectors are designed to carry therapeutic DNA into target cells, where that genetic material can, for example, support production of a functional protein or another intended therapeutic effect, depending on the product design. In practice, successful delivery depends on both the biology of the vector and the way the product has been developed, including capsid selection, the therapeutic sequence itself, and the target tissue.

AAV is one of the most established gene therapy platforms because it offers several important advantages:

• low pathogenicity 
• tissue targeting potential through different serotypes and capsids 
• a strong and growing clinical track record 
• the potential for sustained gene expression 
• broad relevance across multiple therapeutic areas 

Its versatility has made AAV a leading platform in gene therapy development, although that does not remove the manufacturing and analytical challenges that can arise as products become more complex.

Like all advanced therapies, AAV-based gene therapy carries risks that need to be carefully understood and managed. These can include immune responses to the vector, dose-related toxicities, variability in patient response, and challenges related to product quality and consistency. Careful vector design, product/process development, analytics, and clinical oversight are all important in supporting a well-controlled programme.

AAV manufacturing becomes more challenging as products move beyond established designs and into more complex development programmes. Common issues include maintaining product quality during scale-up, removal of empty or partial capsid impurities, achieving batch consistency, and developing suitable analytical methods to allow full product characterisation. These challenges can become even more pronounced when novel capsids or more complex vector designs are involved, making process robustness and product understanding increasingly important.

AAV vector design has a direct influence on how a product performs during manufacturing. Factors such as capsid selection, genome structure, and payload size can affect yield, purification behaviour, packaging efficiency and impurity profile. In practice, this means that early design choices can have a significant effect on scalability and on how straightforward, or difficult, downstream manufacturing becomes.

Empty capsids are AAV particles that contain little or no genetic material, while partial capsids often contain incomplete genomes. These are common product-related impurities in AAV manufacturing, and they matter because they can potentially impact potency, can be immunogenic, complicate product characterisation, and increase the burden on both purification and analytics. Managing capsid impurities is therefore an important part of AAV process development and GMP manufacturing.

A strong analytical strategy is essential in AAV gene therapy because product quality cannot be managed effectively without the right level of product understanding. Analytics are used to assess potency, genome integrity, assurance of dose, capsid composition, and impurities, while also supporting process development and comparability during manufacturing changes. As AAV products become more complex, standard assays may not always provide enough insight, so a more tailored analytical approach may be needed to reduce development risk and support manufacturing readiness.

Engineered AAV capsids can improve tissue targeting or help address biological barriers, but they can also introduce new manufacturing and analytical complexity. This is because modifications to the capsid may affect how the vector behaves during production, purification, and characterisation. In practice, engineered capsids may behave differently in purification, show altered stability and require more tailored analytical methods or reference standards than established serotypes. As a result, they often need a more product-specific development strategy rather than relying solely on standard platform approaches.

Recent advancements in AAV vector technology are focused on improving therapeutic performance while supporting more effective development and manufacturing strategies. These include:

• engineered capsids for improved tissue targeting 
• immune evasion strategies 
• dual-vector approaches for larger payloads 
• improved analytical methods for product characterisation 
• more robust and scalable manufacturing and purification platforms 

These developments are expanding what AAV therapies may be able to achieve, but they can also increase demands on process development, analytics, and GMP readiness.